Does VEMURAFENIB Cause Malignant neoplasm progression? 98 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 98 reports of Malignant neoplasm progression have been filed in association with VEMURAFENIB (ZELBORAF). This represents 1.1% of all adverse event reports for VEMURAFENIB.
98
Reports of Malignant neoplasm progression with VEMURAFENIB
1.1%
of all VEMURAFENIB reports
34
Deaths
22
Hospitalizations
How Dangerous Is Malignant neoplasm progression From VEMURAFENIB?
Of the 98 reports, 34 (34.7%) resulted in death, 22 (22.4%) required hospitalization, and 7 (7.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEMURAFENIB. However, 98 reports have been filed with the FAERS database.
What Other Side Effects Does VEMURAFENIB Cause?
Rash (1,202)
Arthralgia (783)
Off label use (782)
Fatigue (773)
Diarrhoea (655)
Nausea (601)
Pyrexia (569)
Death (505)
Alopecia (445)
Decreased appetite (383)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which VEMURAFENIB Alternatives Have Lower Malignant neoplasm progression Risk?
VEMURAFENIB vs VENETOCLAX
VEMURAFENIB vs VENLAFAXINE
VEMURAFENIB vs VENTAVIS
VEMURAFENIB vs VENTOLIN
VEMURAFENIB vs VENTOLIN HFA